Skip to main content

Table 1 Characteristics of patients switching between TNF antagonists

From: DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists

 

1st TNF antagonist (417)

2nd TNF antagonist (83)

3rd TNF antagonist (18)

Age, years (SD)

53 ± 13

52 ± 12

44 ± 11

Gender (F)

342 (82%)

68(82%)

17(94%)

Disease duration years (SD)

10.4 (± 8,2)

10 (± 8)

11(± 8)

RF positive, %

68%

69%

61%

Radiographic erosions, %

74%

79%

94%

Concomitant DMARD, %

94%

94%

100%

   Methotrexate

78%

71%

50%

   Leflunomide

8%

2%

17%

   Antimalarial

5%

4%

5%

Oral glucocorticoids, %

83%

83%

51%

Adalimumab, n

38

36

12

Etanercept, n

141

46

5

Infliximab, n

238

1

1